The central lab market has displayed robust growth over the previous years.
• The market size expanded from $3.06 billion in 2024 to $3.31 billion in 2025, marking a stable compound annual growth rate (CAGR) of 8.2%.
This historical growth has been propelled by factors including increased clinical trials, growth in drug development activities, regulatory compliance, increased healthcare research, and a surge in diagnostic testing.
The central lab market is poised to witness significant growth in the near future.
• The market is projected to reach $4.54 billion by 2029 with an 8.2% CAGR.
The growth drivers for the market during this period include increasing personalized healthcare, rising biomarker research, growing demand for telemedicine and remote monitoring, global health challenges, and an escalating demand for precision diagnostics. Technological advancements, innovative solutions, strategic collaborations are key trends anticipated to shape the market dynamics.
One main growth driver propelling the central lab market is the rise in the number of clinical trials. Clinical trials, used to evaluate the safety and effectiveness of new treatments, drugs or medical devices, have seen an increase as pharmaceutical and biotechnology companies are outsourcing central labs for testing and development of new products. For instance, according to the Association of the British Pharmaceutical Industry, the total number of industry-sponsored clinical trials in the UK rose by 4.3%, from 394 trials in 2021 to 411 in 2022.
The central lab market illustrated in this report is set out into different segments –
1) By Service Type: Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology or Histology, Specimen Management And Storage, Special Chemistry Services, Other Service Types
2) By Test Type: Human And Tumor Genetics, Clinical Chemistry, Medical Microbiology And Cytology, Other Esoteric Tests
3) By End-User: Pharmaceutical Companies, Academic And Research Institutes, Biotechnology Companies
Companies in the central lab market are focusing on delivering comprehensive diagnostic services for various cancer diagnostic services. For example, in June 2022, Karkinos Healthcare launched the Advanced Centre for Cancer Diagnostics and Research to revolutionize cancer diagnostics and treatment, focusing on molecular and genomic analysis to improve early detection and treatment options.
The key players propelling innovation in the central lab market include:
• Celerion Inc.
• Cerba Research
• Cirion Biopharma Research Inc.
• Clinical Reference Laboratory Inc.
• Eurofins Central Laboratory LLC
• Frontage Laboratories Inc.
• Icon Central Labs
• Interlab Central Lab Services
• InVitro International
• LabConnect LLC
• Labcorp Drug Development India Private Limited
• Medpace Clinical Research India Private Limited
• MLM Medical Labs GmbH
• Q2 Solutions Pty Ltd.
• Sonic Healthcare Limited
• Synevo Central Lab
• Acm Global Laboratories Private Limited
• Altasciences
• Barc Lab
• BioIVT LLC
• ICON plc
• Intertek
• LabNow LLC
• Medidata Solutions
• NAMSA LLC
• Neoteryx
• Northwell Health Labs
• PAREXEL International
• Pharm-Olam LLC
• Pharmaceutical Product Development
• PRA Health Sciences
• Quest Diagnostics
• IQVIA Co.
• Rho Inc.
North America led the central lab market in 2024. However, Asia-Pacific is forecasted to be the fastest-growing region during the forthcoming period. The central lab market report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.